Otrivin is owned by Haleon (the United Kingdom, LSE: HLN), which was separated from GSK on 18 July 2022.[1][2] Before Haleon, Otrivin was owned by GSK from 2015 to 2022.[2]
Otrivin is a nasal decongestant spray using xylometazoline, launched in 1953 and sold in more than seventy countries. It is one of the largest brands in a category otherwise dominated by local names.
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Haleon ownership tree →
GSK demerged its consumer healthcare business as Haleon, listing it in London and New York in July 2022. The business already contained Pfizer's consumer health portfolio, contributed to a joint venture in 2019, which is how Advil and Centrum came to sit alongside Sensodyne and Panadol.
No tagged news items yet. Headlines are added nightly from public feeds; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
The parent company of Otrivin is Haleon, a publicly listed company headquartered in the United Kingdom.
Otrivin originated in Switzerland in 1953, but it is owned today by Haleon, which is headquartered in the United Kingdom. So Otrivin is a Swiss-origin brand under British ownership.
Haleon has owned Otrivin since 18 July 2022.
Before Haleon, Otrivin was owned by GSK from 2015 until 2022.
Yes. As of 6 September 2026, Otrivin is still owned by Haleon. The ownership record was last checked against primary sources on that date.
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.